Drugs Developed Against Cancer's 10 Hallmarks

Successful cancer treatments target particular biomarkers and their pathways. Our previous article discussed "Cancer's 10 Hallmarks". Effective treatments have been developed against each of the 10. Some remain in clinical trials, and effectiveness varies by cancer type and stage. These treatments include;
1) Growth factor inhibitors: Cancer cells increase growth factors or alter their receptors, producing continuous “proliferate” signals. Drugs target growth-promoting factors, blocking their binding and further proliferation. Examples include Cetuximab and Panitumumabas such drugs.
2) Cyclin-Dependent Kinase Inhibitors: Cancer cells evade growth-inhibiting proteins. Increased cyclin-dependent kinase activity causes proliferation, so researchers designed molecules blocking it. Examples are Palbociclib and Letrozoleamong these drugs.
3) Anti-CTLA4 Therapies: Cancer cells learn to become invisible to immunity by carrying proteins making normal cells appear friendly. Drugs prevent immune fighter T cells from binding proteins that make cancer cells appear friendly. The best known are Ipilimumab, Pembrolizumab, Nivolumab and Atezolizumabas such drugs.
4) Telomerase Inhibitors: Cancer cells can continually proliferate by increasing telomerase enzyme activity. Telomerase primarily prevents deterioration of gene-protecting sequences called telomeres is to prevent disruption of the sequences bearing this name that protect genes. Clinical trials aimed at developing these drugs are still ongoing.
5) Anti-Inflammatory Drugs: Tumor tissue generally contains inflammation-related immune cells. Increased numbers intensify inflammation and cancer progression. These cells also produce free oxygen radicals and increase DNA damage. Examples include nonsteroidal drugs such as aspirin. Numerous aspirin studies concern, rather than treatment, cancer preventionin cancers such as colorectal cancer.
6) HGF, c-Met Inhibitors: After reaching a certain proliferative capacity, cancer cells migrate to other tissues and organs. Metastasis accounts for 90 percent of cancer deaths. C-met and HGF proteins increase proliferation and support migration (metastasis). Drugs designed for this include Crizotinib and Cabozantinibas examples.
7) Aerobic Glycolysis Inhibitors: Rapidly dividing cancer cells need much energy. These drugs primarily aim to cut energy supplies. Clinical trials continue. 8) VEGF inhibitors: Cancer cells form vessels to obtain extra nutrients and oxygen. Increasing VEGF proteins causes vessel systems to form. Drugs designed for this include Bevacizumab and Regorafenibas examples.
9) PARP Inhibitors: Most cancer drugs aim to destroy cancer cells by damaging DNA. PARP (Poly ADP ribose) proteins repair DNA. Cancer cells increase PARP activity to protect their DNA. Examples of these drugs include Olaparib and Veliparibas examples.
10) Cell Death-Promoting Proteins: Cancer cells evade programmed death called apoptosis. Researchers designed biological molecules resembling the BH3 proteinthat enables programmed cancer cell death. Increasing this protein leads cancer into programmed death. An example is Bortezomibas examples.
Each day, cancer research discovers new characteristics. In the near future, gene therapies targeting cancer's origins, immunotherapies and treatments targeting multidrug resistance will gain importance.
Sources
Hallmarks of Cancer: The Next Generation
Cell, Volume 144, Issue 5, 646 – 674.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.